OXiGENE, Inc.
OXGN, a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that the company has amended the
Limited Distribution Agreement, established in December 2011, with Azanta
Danmark A/S to include additional territories. The territory originally
included the European Union, including the Nordic countries and Switzerland,
and Canada. The expanded territories now include Israel and South Korea. The
Limited Distribution Agreement provides access to ZYBRESTAT® for the treatment
of patients in Europe with anaplastic thyroid cancer (ATC) on a compassionate
use basis via a named patient program, managed by Azanta A/S. The Agreement
provides a regulatory mechanism to allow healthcare professionals in Europe to
prescribe ZYBRESTAT to individual ATC patients while it is still in
development.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in